The global women’s health therapeutics market size is
expected to reach USD 210.9 billion by 2025, according to a new report by Grand
View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the
forecast period. Entry of effective drugs, a rise in awareness about early
diagnosis and treatment, along with prevalence of chronic diseases are among
the key factors likely to drive the market during the forecast period.
The women’s health therapeutics market
is expected to witness high growth in the forthcoming years due to increasing
investment by key market players to fulfill demand in areas of infection,
cancer, and pregnancy-related complications. In October 2016, Prelude
Fertility, Inc. received USD 200 million from the Reproductive Biology
Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing
fertility services and treatment to people with delayed childbirth. Juneau
Biosciences, LLC has deployed USD 35 million until 2017 towards development of
molecular diagnostics and therapeutics for endometriosis (uterus) conditions.
In January 2018, Melinta Therapeutics,
Inc. acquired The Medicines Company’s infectious diseases business. This
acquisition would help to the former expand its portfolio by offering
life-saving treatment options. In November 2017, Biocon launched KRABEVA, a
biosimilar used for the treatment of metastatic colorectal, cervical, ovarian,
and brain cancer. Increasing investments by top market players are anticipated
to propel the global market over the forecast period.
There is significant unmet need
associated with treatment options for female sexual dysfunction. Currently,
there are no Food and Drug Administration (FDA)-approved drugs for the
treatment of female sexual dysfunction and many promising molecules are in late
stage of development phase. Some of these molecules include LibiGel by BioSante
Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II
of clinical trials respectively in U.S.
Browse full research report on Women’s Health Therapeutics Market: https://www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market
Further key findings from the report suggest:
- By type, infection accounted for the largest market share in
2017 and is expected to maintain its dominance during the forecast period
due to rising drug approvals, availability of diagnostic tests and
treatments, and high incidence of infectious diseases
- Ovarian cancer is anticipated to be the fastest-growing
sub-segment of oncology during the forecast period due to high prevalence
of ovarian cancer and approval of new and improved drugs
- North America is expected to maintain its dominance in the
coming years due to high awareness about women’s health, increase in
number of advanced diagnostic and treatment methods, mergers and
acquisitions by market players, and rise in infections and cancer cases
- Asia Pacific is likely to witness significant growth over the
next decade due to improving healthcare facilities, increase in
commercialization and approval of products, and investment by market
players
- Some of the key players in women’s health therapeutics market
are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd,
AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company,
Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V.,
Sun Pharmaceutical Industries Ltd, and Sanofi.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market/request/rs1
Grand View Research has segmented the global women’s health
therapeutics market based on type and region:
Women’s Health Therapeutics Type Outlook (Revenue, USD Million,
2014 - 2025)
- Infection
- Pregnancy
- Oncology
- Cervical
Cancer
- Ovarian
Cancer
- Uterine
Cancer
- Vaginal
& Vulvar Cancer
Women’s Health Therapeutics Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Asia
Pacific
- China
- Japan
- India
- Latin
America
- Brazil
- Mexico
- Middle
East & Africa
- South
Africa
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
No comments:
Post a Comment